tci Medicare Compliance & Reimbursement - 2016 Issue 6
Why New Part B Drug Model Could Hit Oncology the Hardest
Subscribe or sign in to view the full article.
Article Overview
This article examines a proposed Medicare Part B drug payment model and the reaction from major oncology organizations. It summarizes their concerns about how payment policy changes may affect oncology practices, patient access to physician-administered drugs, and broader care delivery trends. The piece is relevant to providers, practice managers, reimbursement professionals, and policy readers following Medicare payment reform and cancer care economics.
Why This Topic Matters
Medicare Part B drug reimbursement affects physician offices and hospital outpatient departments, especially in oncology where high-cost drugs are common. Readers interested in reimbursement policy, oncology practice economics, and access-to-care implications will want to understand the issues raised in the article.
What You Will Learn
- The policy context behind proposed Medicare Part B drug payment changes
- Why oncology organizations are concerned about reimbursement impacts
- How advocacy groups frame the relationship between payment policy and cancer care delivery
- What broader trends in oncology site-of-care consolidation are being discussed
Who Should Read This
- Oncologists
- Oncology practice administrators
- Medical coders and billing staff
- Reimbursement and revenue cycle professionals
- Health policy analysts
- Hospital outpatient department managers
Subscribe or sign in to view the full article.
Thank you for choosing Find-A-Code, please Sign In to remove ads.
Quick, Current, Complete - www.findacode.com